|
21 Aug 2018 |
Social |
TB Study of 550 RA, PsA, AS patients on TNF inhibitors from Romania (population risk is 97 per100k PY): incidence of TB on TNFi to be 1348.0, 862.1 and 540.2 per 100k Pt-Yrs (measured as TST >5, TST>10mm, QFT) https://t.co/SIkefJg909 |
|
|
03 Aug 2018 |
News |
Higher Infection Rates for Infliximab in Psoriasis |
|
|
19 Jul 2018 |
News |
Biomarker Combo Predicts TNF Inhibitor Responses |
|
|
12 Jun 2018 |
News |
TNF Inhibitors Don't Increase Cancer Risk in Children |
|
|
11 Jun 2018 |
News |
Risk of Psoriasis Complicating TNF Inhibitor Therapy |
|
|
09 Apr 2018 |
News |
Favorable Certolizumab Safety Profile in Pregnancy |
|
|
05 Mar 2018 |
News |
Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept |
|
|
20 Feb 2018 |
News |
Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk |
|
|
20 Feb 2018 |
Social |
PANTS study:Personalized anti-TNF Therapy in Crohn Disease tests real-world eficacy, safety & immunogenicity of infliximab vs biosimilar CT- P13 vs adalimumab. Wk 54 remission rate was 40% INFX, 40% CTP13 & 34% in ADA; immunogenicity was 26%, 28%, 11%
https://t.co/irhImH6ipP |
|
|
12 Feb 2018 |
Social |
RT @uptoTate: Obesity as a predictor for poor TNFi response in IBD. Dr. U. Mahadevan #RWCS @RheumNow https://t.co/nmCljYcaqJ |
|
|
10 Feb 2018 |
Social |
RT @uptoTate: Likelihood of achieving remission in patients who’ve failed one TNFi. Dr. M. Genovese #RWCS @RheumNow https://t.co/kFt0InT5q5 |
|
|
26 Jan 2018 |
Social |
RheumNow Wk in Review is up. Discussing MPO bronchiectasis, $$ biologics, comorbidity in myositis, secondary TNF failure & ADAbs. Listen here https://t.co/wmVyjrzOB1 Watch there https://t.co/32q2qojDZC |
|
|
25 Jan 2018 |
News |
Obesity Outweighs Psoriasis in Comorbidity Risk with Children |
|
|
25 Jan 2018 |
News |
Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures |
|
|
24 Jan 2018 |
News |
PRESERVE Study: HAQ, BMI and Age Predict Responses to Combo Therapy |
|
|
12 Jan 2018 |
Social |
188 PsA pts receive 1st TNFi, 27% D/C by 24 mos (1/3 for primary inefficacy, 22% secondary inefficacy, 43% adverse events) Predictors of failure = female or metabolic syndrome-co-morbidities (HR = 2.65). https://t.co/VRdikUSQ0f |
|
|
08 Dec 2017 |
News |
Why TNF Inhibitors May Work in Some Autoinflammatory Patients |
|
|
07 Dec 2017 |
News |
Infliximab Does Not Increase Perioperative Infection |
|
|
21 Nov 2017 |
ACR Video |
Dr. Rachel Tate: Sarcoidosis and TNF Inhibitors |
|
|
08 Nov 2017 |
Social |
RT @uptoTate: 84% of cardiac sarcoidosis pts refractory to immunosuppressive tx responded to TNFi. #ACR17 @RheumNow #2904 https://t.co/vTOL… |
|
